We combine Passion, Proficiency and Purpose
Problem inspired, Technology driven, we deliver the Healthcare Innovation that works.
RoseBio was formed in March 2024 as a spin-off from Italy’s renowned National Research Council (CNR), leveraging over seven years of dedicated platform development and validation. The initial strides towards applications of ZipArray in optimisation of treatments for cancer and tuberculosis, were catalysed by extensive collaborations with clinical institutions throughout Italy and the European Union. With a wealth of expertise in assay industrialization and clinical validation, the team is poised to transcend boundaries, steering the utility of precision diagnostics across diverse high-value domains of healthcare.
Founding Team
Marcella Chiari, PhD
CEO, CTO
Marcella Chiari
Chief Executive Officer, Chief Technology Officer
Marcella Chiari is a Pharmaceutical Chemist, internationally renowned for her expertise in polymeric coatings for microchip electrophoresis and microarrays. Throughout her distinguished career at the National Research Council of Italy, she has formed and led a multidisciplinary team of organic and bioorganic chemists, computational chemists, biochemists, and biotechnologists. Her research covers the entire spectrum of microarray technology, from surface modification to the development of clinically relevant bioassays. She is the inventor of a family of copolymers which limitless potential as a surface-coating material has been universally recognized and deployed to enhance the performance of assays, sensors and analytics in research and clinical applications. Marcella owns several international patents and has authored over 250 publications in international peer-reviewed journals and has coordinated numerous national and international projects. She is also a co-founder of Lucidant Polymer, a successful California-based company specialized in high-quality, high-value polymer production.
Why RoseBio?
“From the very moment we developed this groundbreaking method for detecting mutations in circulating DNA, I felt a strong desire to share this invention and utilize it for the benefit of the cancer patient community. I envision RoseBio as the bridge between scientific discovery and practical application”.
Alessandra Fischetti, PhD
COO
Alessandra Fischetti
Chief Operations Officer
With a Master’s Degree in Nuclear Engineering from the Polytechnic of Milan, Alessandra Fischetti has dedicated 25 years to developing and commercialising innovative solutions within the life sciences and diagnostics sector. Alessandra has honed her technology and market expertise within companies such as STMicroelectronics, Hewlett Packard, Scienion, Cellenion, while acting as a pioneer and promoter of the technologies that contributed to growth of genomic and proteomic market, including NGG target enrichment, single-cell technologies and lab-on-chip. Today, Alessandra is recognized as a leading expert in translating R&D into industrial production of biosensors and multiplexing diagnostics tests. She currently commercializes RUO and IVD-CE products in Italy through her own company, BIOTT. As VP of Asia Sales for SCIENION, she has ongoing contacts with many leading biotech and biosensor platform providers, leveraging an extensive commercial and distribution network that spans across Asia and Europe.
Why RoseBio?
“At that time the “dual-probe” technology first emerged, several years ago, liquid biopsies and precision diagnostics were just hopeful concepts. Today, they are still a reality for a select few. With RoseBio, I am committed to making precision diagnostics and personalized treatments accessible to patients worldwide”.
Natasa Zarovni, PhD
CSO
Natasa Zarovni
Chief Strategy Officer
Natasa Zarovni is a trained molecular biologist and physiologist with a PhD in Molecular Medicine from Open London University and University Vita Salute in Milan, and an over decade long academic research and project management experience in gene therapy, cancer immunology, stem cells, functional genomics. She was a key member of foundational scientific team of Hansabiomed OU and Exosomics Srl, where she has worked as the R&D and Strategic Innovation Leader on building up the team, the IP portfolio, product pipeline and grants supported projects. Over last 15 years she has built an excellent scientific and non-dilutive fund-raising track record and has established herself as an expert in Exosome and Liquid Biopsy. Through her active promotion and participation in over 20 collaborative projects, she has been supporting the growth of the overall EV Innovation and Research-to-Business ecosystem across EU. Today Natasa is putting all her expertise and enthusiasm by acting as a strategy and innovation lead in dedicated companies developing the products that will make a true difference in reshaping our healthcare.
Why RoseBio?
“Cancer has marked my professional and personal history, like that of many others. For such a complex disease the only true prevention is prompting the early and accurate detection, enabling timely and accurate intervention”
Francesco Damin, PhD
Senior Product Manager
Francesco Damin
Senior Product Manager
Francesco Damin is an expert in Molecular Biology, with a career dedicated to scientific innovation. He graduated in Biological Science, specializing in Molecular Biology, from the University of Milano in 1998. After several years of fellowships and research contracts, in 2011, he was appointed as a research scientist at the Institute of Molecular Recognition Chemistry of the National Research Council of Italy, now known as the Institute of Chemical Sciences and Technologies “G. Natta” (SCITEC). His research, documented by over 80 peer-reviewed articles, focuses on developing surfaces for the analysis of DNA and proteins using microarray technology. Francesco has made significant contributions to molecular diagnostic methods for the identification of viral and bacterial pathogens, mutated genes, and chromosomal translocations associated with onco-haematological diseases. He has also developed protein microarrays for advanced diagnostics at reduced costs. His passion for research continues to drive his contributions to evolving molecular biology solutions that address global health challenges.
Why RoseBio?
“To be a part of a liquid biopsy company for cancer diagnosis means becoming part of a groundbreaking journey, where every new step brings us closer to a future where early detection and personalized treatment are within everyone’s reach”.
Silvia Galbiati, PhD
Application Development Scientist
Silvia Galbiati
Application Development Scientist
Silvia Galbiati is a devoted clinical researcher. Since she obtained her qualification as a molecular biologist in 2000, she has worked in the field of the identification of minority mutated alleles at the San Raffaele Hospital, acquiring a strong background in the most sensitive and, at the same time, innovative molecular techniques to address this problem. She has extensive know-how in the analysis of nucleic acids (both DNA and RNA) in plasma, developing, comparing, and validating protocols with high sensitivity and accuracy. In particular, she shows extensive experience in non-invasive prenatal diagnosis of genetic diseases and in liquid biopsy, looking at circulating cell free tumor DNA, as documented by numerous publications on peer-reviewed international journals. Her professional experience attests to her scientific curiosity and interest in different biological topics and her approach in addressing these issues with the most up-to-date informative technologies.
Why RoseBio?
“For a researcher there is no greater satisfaction than seeing one’s ideas and knowledge “exploited” for the public good. RoseBio represents a challenge; it is the conclusion and at the same time the beginning of a new promising path”.
Paolo De Stefanis
President of the Board
Paolo De Stefanis
President of the Board
Paolo De Stefanis is Electrical Engineer a founder and CEO of Day One Innovation Studio. Product innovation is his passion, fueled by logic and empathy. His engineering background keeps him grounded in tech, while a touch of “psychologist” lets him connect with the vision of aspiring entrepreneurs. High-tech startups are his daily dose of inspiration: over the years, he has help with bringing tens of innovative ideas to life through the launch of new products and startups, securing over €100 million through VC firms and public funding.
Why RoseBio?
“Witnessing scientists turn their dreams into reality – that’s what fuels my fire every day. RoseBio is solving a pressing healthcare challeng, and being part of it keeps me in my comfort zone where innovation and entrepreneurship thrive”.
Keep Pace, Pave the Way
Our technology is supported by science, our team is backed by an innovation ecosystem, and our mission fueled by the healthcare transformation. Check our publications and news selection
